Eurofarma
Eurofarma, officially known as Eurofarma Laboratórios S.A., is a prominent Brazilian pharmaceutical company headquartered in São Paulo, Brazil. Established in 1972, Eurofarma has grown to become a key player in the Latin American pharmaceutical industry, with a strong presence across various operational regions, including Central and South America. Specialising in the development, manufacturing, and marketing of prescription medicines, generics, and over-the-counter products, Eurofarma is recognised for its commitment to quality and innovation. The company’s diverse portfolio includes therapeutic areas such as oncology, cardiology, and central nervous system disorders, setting it apart with its focus on patient-centric solutions. With a robust market position, Eurofarma has achieved significant milestones, including numerous certifications and awards for excellence in pharmaceutical practices, reinforcing its reputation as a trusted name in healthcare.
DitchCarbon Score
How does Eurofarma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Eurofarma's score of 36 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Eurofarma's reported carbon emissions
In 2023, Eurofarma reported total carbon emissions of approximately 42,183,000 kg CO2e. This figure includes 16,990,000 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and 7,963,000 kg CO2e from Scope 2 emissions, related to indirect emissions from purchased electricity. Notably, Scope 3 emissions accounted for about 17,230,000 kg CO2e, which includes emissions from business travel, employee commuting, and waste generated in operations. Over the years, Eurofarma's emissions have shown a trend of increase, with total emissions rising from approximately 23,351,000 kg CO2e in 2019 to 42,183,000 kg CO2e in 2023. The company has not publicly disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges, indicating a potential area for future commitment and improvement in their sustainability strategy. Eurofarma's emissions data reflects the challenges faced by the pharmaceutical industry in managing carbon footprints, particularly in Scope 3 emissions, which often represent the largest share of total emissions. The company’s headquarters in Brazil positions it within a region increasingly focused on sustainability and climate action, suggesting that further commitments could enhance its environmental performance and reputation.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 12,594,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 4,611,000 | 0,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 6,146,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Eurofarma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
